Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

993.64 +11.42 (+1.16%)
Official Closing Price Updated: 7:00 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
US Stock Market Rides High: Fed Rate Cut Fuels Optimism as Indices Eye Record Peaks
New York, NY – December 10, 2025 – The U.S. stock market is currently experiencing a robust rally, with major indices positioned tantalizingly close to their all-time highs. This bullish sentiment,... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Golden Cross Alert: 3 Stocks With Major Upside Potential ↗
Via MarketBeat
The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In ↗
Via Stocktwits
Why Did Structure Therapeutics Stock Surge Pre-Market Today? ↗
Via Stocktwits
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Top 3 Investment Themes That Will Dominate 2026 ↗
Via MarketBeat
News headline image
What&#39;s Happening With French Biotech Abivax Stock On Wednesday? ↗
Abivax shares rise on renewed takeover speculation tied to Eli Lilly following strong Phase 3 trial results. 
Via Benzinga
News headline image
3 Absurdly Cheap Stocks That Look Like Steals Right Now ↗
These stocks are down more than 20% this year, but they possess lots of upside potential over the long term. 
Via The Motley Fool
Topics Economy World Trade
News headline image
2 Pharmaceutical Stocks to Buy at a Discount ↗
Investors are currently so focused on one type of drug that even good companies are being left on the sidelines. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly&#39;s $6 Billion Alabama Site To Make Next-Gen Weight Loss Pills ↗
Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create 450 jobs. 
Via Benzinga
News headline image
Manufacturing Renaissance Fuels Job Market Amidst Shifting Sands
The American labor market is experiencing a fascinating dichotomy as it navigates late 2024 and 2025. While overall job creation has shown signs of moderation and significant revisions to earlier... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Eli Lilly Stock Falls For 9 Straight Days Despite $6B Push To Build A US Plant For Its Oral GLP-1 Pill ↗
Eli Lilly is expanding its U.S. manufacturing footprint with a new Alabama facility that will add thousands of jobs. 
Via Stocktwits
News headline image
Healthcare Sector Falters: S&P 500's Biggest Loser Amid Broader Market Caution
New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Prediction: This Surprising Growth Stock Will Reach -- and Stay in -- the Trillion-Dollar Club in 2026. ↗
A new revenue driver may be just ahead. 
Via The Motley Fool
News headline image
Silver Shines as Global Tariff Storm Gathers: A Safe-Haven and Strategic Imperative in 2025
As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
1 Major Factor Behind the Healthcare Sector's Recent Surge ↗
Blockbuster drugs are a major driver of the growth of healthcare stocks. 
Via The Motley Fool
News headline image
5 Bold Predictions for the Stock Market in 2026 ↗
Here are some things I think are more likely to happen in 2026 than the experts seem to believe. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Global Markets Brace for Fed Decision Amidst Divergent Policies and Geopolitical Crosscurrents
Global financial markets are treading a cautious path as December 9, 2025, unfolds, with investors keenly focused on the impending U.S. Federal Reserve's interest rate decision. The highly anticipated... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
2 Potential Stock Splits to Watch for in 2026 ↗
After experiencing incredible rallies during 2025, these two stocks could decide to "split it" in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
JPMorgan's Cautious Outlook Rattles Dow Jones Amidst Strong Performance
JPMorgan Chase & Co. (NYSE: JPM), a titan of the financial industry and a significant component of the Dow Jones Industrial Average (DJIA), recently experienced a notable shift in market sentiment.... 
Via MarketMinute
Topics Artificial Intelligence Credit Cards Economy
News headline image
Why Novo Nordisk Stock Was Melting on Monday ↗
It continues to be pounded by competition and challenges coming from numerous directions. 
Via The Motley Fool
News headline image
Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗
Market-based odds now show an 87% chance of a rate cut. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Eli Lilly Scores Huge Win As China Adds Mounjaro To National Insurance — But Raises Fears Of A Brutal Pricing War ↗
Eli Lilly and Co (NYSE: LLY) announced that its diabetes drug, Mounjaro, will be added to China's state-run health insurance scheme from January 1, 2026. 
Via Benzinga
News headline image
Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip? ↗
This is no reason to panic. 
Via The Motley Fool
Topics Government
News headline image
ELI LILLY & CO (NYSE:LLY) Offers a High-Quality Dividend Backed by Strong Profitability and Growth ↗
Eli Lilly offers a stable, growing dividend backed by exceptional profitability and solid financial health, making it a prime pick for long-term dividend growth investors. 
Via Chartmill
News headline image
Do These 3 Healthcare Stocks Need a Checkup? ↗
These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Meet the Supercharged Growth Stock That Could Join Apple, Nvidia, Microsoft, and Alphabet in the $2 Trillion Club by 2028 ↗
Eli Lilly's stock price and market cap are poised to explode with the GLP-1 market. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? ↗
The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable. 
Via The Motley Fool
News headline image
With Netflix's 10-for-1 Stock Split Complete, Here Are 3 Growth Stocks to Buy in December That Could Issue Stock Splits in 2026 ↗
Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new year. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Trump Administration Eases Investment Deadlines For Large Pharma Companies: Report ↗
The report added that at least one of these companies expects to fulfill the multi-billion-dollar investment pledge in full by Jan. 1, 2029. 
Via Stocktwits
Topics Artificial Intelligence Government Workforce
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.